Renal epithelioid angiomyolipoma (eAML) is considered a malignant variant of angiomyolipoma (AML). From 2001 to 2016, a total of 570 patients were diagnosed with renal AML in Linko Chang Gung Memorial Hospital, Taiwan, including 23 cases of renal eAML.
| INTRODUCTION
Renal epithelioid angiomyolipoma (eAML) has been considered a malignant variant of classic angiomyolipoma (AML) since it was classified by World Health Organization (WHO) in 2004. Aside from classic AML, which is characterized histologically by its triphasic component (blood vessels, smooth muscle, and adipose tissue), eAML is present with polygonal cells, clear to eosinophilic cytoplasm, and occasional nuclear atypia. 1 Immunohistochemically, perivascular epithelioid cell tumor expresses myogenic and melanocytic markers, such as HMSA-1, HMB45, MelanA/Mart1, microophtalmia transcription factor (Mitf), actin, and desmin. 2 In addition, eAML shows a higher association with tuberous sclerosis complex than does classic AML. 1 When rendered into an image, eAMLs tend to present themselves as a solid lesion with hyperdensity on unenhanced computed tomography (CT) with or without fat components and demonstrate rapid wash-in to slow wash-out dynamic enhancement patterns. 3 Vascular invasion of eAML to renal veins, inferior vena, pulmonary veins, and the right atrium has been reported. [4] [5] [6] [7] Two recent eAML studies conducted by Nese et al. 6 and Brimo et al. 7 have categorized vascular invasion as an adverse parameter to malignant eAML. We intend to classify eAML tumor vascular invasion along with distant metastasis as "invasive eAML." The purpose of this article is to analyze the clinicopathological feature of eAML and provide treatment suggestions.
| MATERIAL AND METHODS
In our institute, a total of 570 patients were diagnosed with renal 
| RESULTS
As shown in Table 1 , in these 23 eAML cases, the average age was Due to a higher potential of adverse events, during the course of our study, we grouped tumors with venous tumor thrombus and/or distant metastasis as "invasive eAML." In our study, the rate of invasive eAML was 21%. (Two distant metastasis and four venous thrombus formation. One of the cases has both distant metastasis and renal vein thrombus.) As shown in Table 2 , pathologically, the five invasive eAML have more severe nuclear atypia (severe rate 80% vs 16%, P = 0.017), higher rates in necrosis (necrosis rate 100% vs 44%,
There is statistically no significance in regards to patients' ages (P = 0.142), tumor sizes (P = 0.247), and mitotic counts (P = 0.054) as involves invasive and noninvasive groups. Some noticeable accompanying characteristics including hemorrhaging, coexisting with AML, and coexisting with renal cell carcinoma are also seen in this series. The incidence of renal vein and inferior vena cava thrombus formation in our series was higher (4 out of 23) than some other studies. 7 4 | DISCUSSION eAML is considered a potentially malignant neoplasm with approximately one-third of distant metastasis rate. 8 To evaluate the exact prognosis of this rare disease, Brimo et al. 7 conducted a study con- The term used to describe cases with poor clinical courses has still not been unified among previous studies. The term "malignant eAML" is still not clearly defined. In our study, a case (case No. 3 in Table 1) was found with a 13.2 cm tumor with inferior vena cava thrombus.
The patient had undergone radical nephrectomy with thrombectomy but without postoperative systemic therapy. Unfortunately, tumor recurrence was found 1 year later in the liver and retroperitoneum.
Owing to the previous study results and our own experience, we believe that tumor thrombus most frequently results in adverse clinical outcomes. Therefore, we tend to directly categorize cases with tumor thrombus and/or distant metastasis as being part of an "invasive group" to emphasis the need for more cautious disease monitoring and earlier intervention. Compared to the noninvasive group, the invasive group shows a higher rate of tumor necrosis and nuclear atypia. Although not statistically significant, we can also see that the invasive group has a tendency towards having a bigger tumor size partial nephrectomy is reserved for tumors <4 cm. 9 In addition, consideration of the location of the tumor within the kidney is essential when selecting cases to undergo partial nephrectomy. We suggest that peripherally located tumors with a tumor size <4 cm is preferential for partial nephrectomy. Although there has yet to be a universal consensus on chemotherapy, there have been reported cases with tumors responding dramatically to everolimus in patients with eAML recurrence. 10 The details of treatment and the usage of next generation sequencing to explore the mTOR receptor pathway of the five invasive cases included in our study was discussed in another study done by Chuang et al.
11
The diagnosis of eAML preoperatively by imaging remains a great challenge. Jinzaki et al. 12 reviewed the current classification of AML and found that on CT, eAML was present as a hyperattenuating mass, including renal cell carcinoma (typically the papillary type), oncocytoma, lymphoma, leiomyoma, metanephric adenoma, and metastases. Therefore, when encountering a renal mass presenting the features mentioned above, a biopsy is recommended for more precise treatment decision-making. 13 We have intended to analyze the tumor component Similar to eAML, renal cell carcinoma also originates from kidney and spreads hematogenously. Thus, after the diagnosis of eAML is made, we recommend treating eAML using the guidelines currently in place for the treatment of renal cell carcinoma, including staging, surgical treatment guidelines and similar intervals for follow-up appointments.
This study is limited to a single institution and the population selection is all Han Chinese.
| CONCLUSION
eAML is a potentially malignant neoplasm. We have identified 23 eAML in 570 AML cases (4%). Five of them (21%) showed invasive behavior including vascular invasion or distant metastasis. The invasive group shows more severe nuclear atypia and higher rates in necrosis. There is statistically no significance in relation to patients' ages, tumor sizes, and mitotic counts between invasive and noninvasive groups. We recommend treating eAML using guidelines for treatment of renal cell carcinoma, including staging, surgical treatment options, and intervals for follow-up appointments. 
